The Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications

Overview

Journal Aging Dis

Specialty Geriatrics

Date 2023 Apr 3

PMID 37008052

Authors

Shuwen Zhang

Junteng Zhou

Wenchao Wu

Ye Zhu

Xiaojing Liu

Affiliations

Soon will be listed here.

Abstract

Bile acids (BAs), key regulators in the metabolic network, are not only involved in lipid digestion and absorption but also serve as potential therapeutic targets for metabolic disorders. Studies have shown that cardiac dysfunction is associated with abnormal BA metabolic pathways. As ligands for several nuclear receptors and membrane receptors, BAs systematically regulate the homeostasis of metabolism and participate in cardiovascular diseases (CVDs), such as myocardial infarction, diabetic cardiomyopathy, atherosclerosis, arrhythmia, and heart failure. However, the molecular mechanism by which BAs trigger CVDs remains controversial. Therefore, the regulation of BA signal transduction by modulating the synthesis and composition of BAs is an interesting and novel direction for potential therapies for CVDs. Here, we mainly summarized the metabolism of BAs and their role in cardiomyocytes and noncardiomyocytes in CVDs. Moreover, we comprehensively discussed the clinical prospects of BAs in CVDs and analyzed the clinical diagnostic and application value of BAs. The latest development prospects of BAs in the field of new drug development are also prospected. We aimed to elucidate the underlying mechanism of BAs treatment in CVDs, and the relationship between BAs and CVDs may provide new avenues for the prevention and treatment of these diseases.

Citing Articles

Senile Osteoarthritis Regulated by the Gut Microbiota: From Mechanisms to Treatments.

Yu F, Zhu C, Wu W Int J Mol Sci. 2025; 26(4).

PMID: 40003971 PMC: 11855920. DOI: 10.3390/ijms26041505.

Short-Chain Fatty Acids and Their Metabolic Interactions in Heart Failure.

Chulenbayeva L, Issilbayeva A, Sailybayeva A, Bekbossynova M, Kozhakhmetov S, Kushugulova A Biomedicines. 2025; 13(2).

PMID: 40002756 PMC: 11853371. DOI: 10.3390/biomedicines13020343.

The Diagnostic Value of Bile Acids and Amino Acids in Differentiating Acute Coronary Syndromes.

Yu Q, Zhao F, Wang S, Jia X, Shen S, Zhao X Int J Gen Med. 2025; 18():179-189.

PMID: 39834909 PMC: 11742763. DOI: 10.2147/IJGM.S499046.

The association of serum total bile acids and deep venous thrombosis.

Li B, Feng X, Kang X, Zhao Y, Cao M, Xu B Thromb J. 2025; 23(1):1.

PMID: 39773208 PMC: 11706104. DOI: 10.1186/s12959-024-00683-8.

Microbiome-metabolome analysis insight into the effects of high-salt diet on hemorheological functions in SD rats.

Qi L, Li Y, Chen Z, Wei C, Wen X, Hu S Front Nutr. 2024; 11:1408778.

PMID: 39381352 PMC: 11460366. DOI: 10.3389/fnut.2024.1408778.

References

Biagioli M, Carino A, Cipriani S, Francisci D, Marchiano S, Scarpelli P . The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. J Immunol. 2017; 199(2):718-733. DOI: 10.4049/jimmunol.1700183. View

Rodriguez A, Mousa A, Ebeling P, Scott D, de Courten B . Effects of vitamin D supplementation on inflammatory markers in heart failure: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018; 8(1):1169. PMC: 5773527. DOI: 10.1038/s41598-018-19708-0. View

Li T, Matozel M, Boehme S, Kong B, Nilsson L, Guo G . Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology. 2011; 53(3):996-1006. PMC: 3079544. DOI: 10.1002/hep.24107. View

Voiosu A, Wiese S, Voiosu T, Hove J, Bendtsen F, Moller S . Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2017; 30(4):392-397. DOI: 10.1097/MEG.0000000000001043. View

Liao Y, Liu C, Xiong T, Zhao M, Zheng W, Feng Y . Metabolic Modulation and Potential Biomarkers of the Prognosis Identification for Severe Aortic Stenosis after TAVR by a Metabolomics Study. Cardiol Res Pract. 2020; 2020:3946913. PMC: 7649585. DOI: 10.1155/2020/3946913. View

Jia W, Wei M, Rajani C, Zheng X . Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell. 2020; 12(5):411-425. PMC: 8106556. DOI: 10.1007/s13238-020-00804-9. View

Vasavan T, Deepak S, Jayawardane I, Lucchini M, Martin C, Geenes V . Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations. J Hepatol. 2020; 74(5):1087-1096. PMC: 8062912. DOI: 10.1016/j.jhep.2020.11.038. View

von Haehling S, Schefold J, Jankowska E, Springer J, Vazir A, Kalra P . Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012; 59(6):585-92. DOI: 10.1016/j.jacc.2011.10.880. View

Mamic P, Chaikijurajai T, Tang W . Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review. J Mol Cell Cardiol. 2020; 152:105-117. PMC: 7981261. DOI: 10.1016/j.yjmcc.2020.12.001. View

10.

Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law J, Cobelli C . The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2012; 62(4):1094-101. PMC: 3609563. DOI: 10.2337/db12-0923. View

11.

Geenes V, Lovgren-Sandblom A, Benthin L, Lawrance D, Chambers J, Gurung V . The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. PLoS One. 2014; 9(1):e83828. PMC: 3885440. DOI: 10.1371/journal.pone.0083828. View

12.

Mayerhofer C, Ueland T, Broch K, Vincent R, Cross G, Dahl C . Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure. J Card Fail. 2017; 23(9):666-671. DOI: 10.1016/j.cardfail.2017.06.007. View

13.

Mozos I . Arrhythmia risk in liver cirrhosis. World J Hepatol. 2015; 7(4):662-72. PMC: 4388994. DOI: 10.4254/wjh.v7.i4.662. View

14.

Song Z, Tian X, Shi Q . Fas, Caspase-8, and Caspase-9 pathway-mediated bile acid-induced fetal cardiomyocyte apoptosis in intrahepatic cholestasis pregnant rat models. J Obstet Gynaecol Res. 2021; 47(7):2298-2306. DOI: 10.1111/jog.14765. View

15.

Voiosu A, Wiese S, Voiosu T, Bendtsen F, Moller S . Bile acids and cardiovascular function in cirrhosis. Liver Int. 2017; 37(10):1420-1430. DOI: 10.1111/liv.13394. View

16.

Yanagida K, Engelbrecht E, Niaudet C, Jung B, Gaengel K, Holton K . Sphingosine 1-Phosphate Receptor Signaling Establishes AP-1 Gradients to Allow for Retinal Endothelial Cell Specialization. Dev Cell. 2020; 52(6):779-793.e7. PMC: 7541081. DOI: 10.1016/j.devcel.2020.01.016. View

17.

Napolitano A, Miller S, Nicholls A, Baker D, Van Horn S, Thomas E . Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014; 9(7):e100778. PMC: 4079657. DOI: 10.1371/journal.pone.0100778. View

18.

Sukocheva O, Furuya H, Ng M, Friedemann M, Menschikowski M, Tarasov V . Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther. 2019; 207:107464. DOI: 10.1016/j.pharmthera.2019.107464. View

19.

Singh S, Khera R, Allen A, Murad M, Loomba R . Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015; 62(5):1417-32. DOI: 10.1002/hep.27999. View

20.

Chevli P, Freedman B, Hsu F, Xu J, Rudock M, Ma L . Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study. Cardiovasc Diabetol. 2021; 20(1):231. PMC: 8653597. DOI: 10.1186/s12933-021-01419-y. View